MIMETAS develops Organ-on-a-Chip-based models for evaluation of new medicines. Our unique microfluidic technology enables testing of compounds on miniaturized 3D organ models in high-throughput. These models are expected to show better predictivity as compared to laboratory animals and conventional 2D cell culture models, without compromising throughput or ease of use.
Hereby we show the establishment of Head and Neck (HN) cancer-derived organoids in 2-lane OrganoPlate®, and its usefulness for phenotypic drug screenings.